3.Zhong X, He P, Chen J, et al. Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial. Gland Surg. 2022;11(1):216-225....
[17]Ismael G, Hegg R, et al.Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. [18]Jackis...
Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9
Holmes FA, Patt D, Manalo Y, et al. Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial. Canc...
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, ner
Abramson V.G., Arteaga C.L., Spring L.M., Waks A.G., et al. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021;11:2474–2487. doi: 10.1158/2159-8290...
PATIENTS AND METHODS: Patients with stage II to III HER2-positive breast cancer underwent tumor biopsy followed by random assignment to paclitaxel plus trastuzumab alone (TH) or with the addition of lapatinib (THL) for 16 weeks before surgery. An investigational arm of paclitaxel plus lapatinib (...
[29]Metzger Filho O,et al.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer:phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.Cancer Discov 2021 May 3:candisc.1557.2020.https://doi.org/10.1158/2159-8290.CD-20-1557. ...
[18]Ahn HK, Sim SH, Suh KJ, et al. Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage Ⅱ/Ⅲ breast cancer: The neo-PATH phase 2 nonrandomized ...